ThromboGenics N.V.'s bet on an erstwhile clot buster in a new ophthalmic indication has turned out to be a lifesaver, as it now is prepping for launch after an FDA panel voted in favor of Jetrea ocriplasmin to treat symptomatic vitreomacular adhesion.

Jetrea is a recombinant, truncated form of the enzyme plasmin, a natural human serine protease that lyses fibronectin, laminin and type IV collagen fibers.